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Abstract
Background:  Our previous proteomic study showed that the senescence marker protein
(SMP30) is selectively present in the plasma of a murine model of acute liver failure (ALF). The aim
of this study was to validate this SMP30 expression in the plasma and liver tissues of mice and
humans with ALF.
Methods: After the proteomic analysis of plasma from a murine model of D-galactosamine/
lipopolysaccharide (GalN/LPS)-induced ALF by two-dimensional electrophoresis (2-DE) and mass
spectrometry, the expression levels of SMP30 in the plasma and liver tissues were validated by
western blot and RT-PCR analyses. These results were then confirmed in plasma samples from
humans.
Results: These data validate the results of 2-DE, and western blot showed that SMP30 protein
levels were only elevated in the plasma of ALF mice. Further analysis revealed that GalN/LPS
induced the downregulation of SMP30 protein levels in liver tissues (by approximately 25% and 16%
in the GalN/LPS-treated mice and in the treated mice that survived, respectively; P < 0.01). Hepatic
SMP30 mRNA levels decreased by about 90% only in the mice that survived the GalN/LPS
treatment. Importantly, plasma obtained from patients with ALF also contained higher levels of
SMP30, about (3.65 ± 0.34) times those observed in healthy volunteers.
Conclusion: This study shows that SMP30 is not only a potential biomarker for the diagnosis and
even prognosis of ALF. It also plays a very important role in a self-protective mechanism in survival
and participates in the pathophysiological processes of ALF.
Background
Comparative proteomics has provided new insights into
the mechanisms and processes of liver disease. Many can-
didate biomarkers have been discovered that are associ-
ated with hepatocarcinoma, viral hepatitis, or liver
cirrhosis [1-4]. However, the proteins identified in these
studies should be examined by other techniques to con-
firm their expression patterns. Because many studies
involve animal experiments, their results should also be
validated in human samples.
In a previous study, we established a murine model of
acute liver failure (ALF) by the administration of D-galac-
tosamine/lipopolysaccharide (GalN/LPS). Using pro-
Published: 28 May 2008
BMC Gastroenterology 2008, 8:17 doi:10.1186/1471-230X-8-17
Received: 3 January 2008
Accepted: 28 May 2008
This article is available from: http://www.biomedcentral.com/1471-230X/8/17
© 2008 Lv et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Gastroenterology 2008, 8:17 http://www.biomedcentral.com/1471-230X/8/17
Page 2 of 7
(page number not for citation purposes)
teomic analysis with two-dimensional electrophoresis (2-
DE) and mass spectrometry, we identified 10 protein mol-
ecules with altered expression in the plasma of ALF mice
[5]. Among these candidate proteins, one protein mole-
cule, senescence marker protein 30 (SMP30), caught our
interest because it only appeared on the 2-D gels of ALF
mouse plasma proteins.
SMP30, an important marker of aging, is a novel protein
expressed mainly in hepatocytes and renal tubule epithe-
lia [6]. Because its structure is highly conserved in various
animal species [7] and its expression is tissue-specific in
hepatocytes, SMP30 has been suggested to play a pivotal
role in the liver. Many researchers have identified the mul-
tifunctional roles of SMP30, such as in the maintenance of
intracellular Ca2+ homeostasis [8] and the regulation of
intracellular signal processes [9]. SMP30 suppressed cell
proliferation in regenerating rat liver and in cloned
hepatoma cells by inhibiting DNA and RNA syntheses in
the nucleus [10-12]. SMP30 also suppressed cell death
and apoptosis in cloned rat hepatoma H4-II-E cells [13].
As a liver-specific protein, elevated plasma levels of
SMP30 have not been reported in ALF. The aim of this
study was twofold: first, to validate the high levels of
SMP30 protein in the plasma of ALF mice and humans;
and second, to examine the expression of SMP30 protein
and mRNA levels in the liver tissues of ALF mice and to
evaluate the potential role of SMP30 in liver failure.
Methods
Animals and treatment
Male BALB/c mice, 18–22 g, were obtained from the Acad-
emy of Military Medical Sciences (Beijing, China). They
were housed and cared for in rooms maintained at a con-
stant temperature and humidity. Food and water were
allowed  ad libitum. Food was withdrawn the evening
before the experiment. All animal experimental proce-
dures were approved by the Ethics Committee of Peking
University People's Hospital before the commencement
of the study.
All mice were randomly divided into eight groups (n = 8
per group), and were given intraperitoneal injections of
D-galactosamine (600 mg/kg body weight; Sigma, Saint
Louis, USA) and lipopolysaccharide (LPS; 8 μg/kg body
weight; Sigma), as described previously [5]. Control ani-
mals were intraperitoneally injected with GalN, LPS, or
saline. Plasma and liver tissue samples were obtained 5
and 24 h after injection and were stored at -80°C until
analysis. Plasma levels of alanine aminotransferase (ALT)
and T-bilirubin (TBiL), measured with a 7170A automatic
analyzer (HITACHI, Japan), were used to assess the extent
of liver injury.
In summary, the eight groups were (1): 5 h after saline
injection; (2): 5 h after LPS injection; (3): 5 h after GalN
injection; (4): 5 h after GalN/LPS injection; (5): 24 h after
saline injection; (6): 24 h after LPS injection; (7): 24 h
after GalN injection; (8): 24 h after GalN/LPS injection.
Plasma protein proteomics
The plasma proteomics protocol was as described in our
previous study [5]. In brief, plasma samples were pooled
and precipitated with cold acetone, then dissolved in
buffer containing 7 M urea, 2 M thiourea, 4% CHAPS, 1
mM EDTA, 50 mM DTT, and 1 mM PMSF. Total protein
concentrations were determined with the Bradford
method. The protein (2 mg) was solubilized in rehydra-
tion buffer containing 6 M urea, 2% CHAPS, 20 mM DTT,
0.5% IPG buffer, and a trace amount of bromophenol
blue. Isoelectric focusing (IEF) was performed with com-
mercially available preformed immobilized pH gradients
(nonlinear, pH 3–7, 24 cm; Amersham, Sweden) using an
IPGphor Isoelectric Focusing System (Amersham). Fol-
lowing a three-step equilibration, the IPG strips were posi-
tioned on 12% polyacrylamide gels and stained with
Coomassie Brilliant Blue G-250 [5]. After they had been
scanned with Labscan (Amersham), the digitized images
of the stained gels were analyzed using ImageMaster 2-D
ver. 5.1 software (Amersham). Only spots that were
present on the experimental gels and were altered at least
twofold compared with the control gels were considered
to be significant and were identified by mass spectrome-
try. After digestion with trypsin (sequencing grade; Roche,
USA), the peptides were processed by liquid chromatogra-
phy-electrospray ionization-tandem mass spectrometry
(LC-ESI-MS/MS). MS/MS spectra were compared with the
NCBI nr-databank using the SEQUEST algorithm.
Western blot (WB) analysis of SMP30
Liver tissues were homogenized in lysis buffer (50 mM
Tris-Cl [pH 8.0], 1% NP-40, 150 mM NaCl, 0.1% SDS,
0.02% sodium azide, and 100 μg/mL PMSF). Plasma pro-
teins (10 μg) or tissue proteins (50 μg) were separated
electrophoretically on SDS-PAGE (12%) and electrotrans-
ferred onto a nitrocellulose membrane (40 V overnight).
The membranes were blocked with nonfat dried milk in
TBS containing 0.2% Tween-20 (TTBS) for 1 h at room
temperature. Membranes were then incubated overnight
at 4°C with goat polyclonal anti-SMP30 antibody
(diluted 1: 300 for plasma and 1:500 for tissues; Santa
Cruz Biotechnology, USA) or rabbit polyclonal anti-β-
actin antibody (diluted 1:1000; Santa Cruz Biotechnol-
ogy). After they had been washed three times in TTBS, the
membranes were reacted with horseradish-peroxidase-
labeled secondary antibody (diluted 1:3000; Santa Cruz
Biotechnology) for 1 h at room temperature. Immunode-
tection was performed with the ECL-Plus kit (Pierce Bio-BMC Gastroenterology 2008, 8:17 http://www.biomedcentral.com/1471-230X/8/17
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technology, USA), according to the manufacturer's
instructions.
Reverse transcriptase-PCR for SMP30 mRNA
Total RNA was isolated from liver tissues with TRIzol Rea-
gent (Invitrogen, USA). First-strand cDNA was generated
from 500 ng of total RNA using an oligo (dT) primer and
SuperScript III reverse transcriptase (Invitrogen). PCR was
performed using Taq DNA polymerase (Qiagen, Valencia,
USA) and oligonucleotide primers for mouse SMP30 (for-
ward 5'-GGAGGCTATGTTGCCACCATTGGAAC-3',
reverse 5'-TTCCCTCCAAAGCAGCATGAAGTTGTTTTA-3',
amplicon size 560 bp) and glyceraldehyde 3-phosphate
dehydrogenase (GAPDH; forward 5'-GTGAAGGTCGGT-
GTGAACGGAT-3', reverse 5'-GCATCCTGCTTCACCAC-
CTTCTT-3', amplicon size 788 bp). The samples were
incubated at 94°C for 2 min, and then amplified for 20
cycles of denaturation for 30 s at 94°C, annealing for 30 s
at 60°C, and extension for 59 s at 72°C. The PCR products
were analyzed by fractionation on a 1.2% agarose gel and
visualized with ethidium bromide staining. Images were
captured using a gel documentation system (Quantity
One, Bio-Rad, USA).
Patient protocol
Plasma samples were obtained from four patients diag-
nosed with ALF. ALF was defined as liver failure with jaun-
dice and an international normalized ratio value of > 1.5
in patients without pre-existing chronic liver disease and
with an illness of less than 26 weeks duration. ALF
resulted from hepatitis B virus infection in two patients
and from antituberculosis drugs in the remaining two
patients. Control plasma samples were obtained from
four healthy volunteers. There were no significant differ-
ences in age or sex between the ALF patient group and the
control group. All samples were stored at -80°C until fur-
ther WB analysis. This study was conducted in agreement
with the Ethics Committee of Peking University People's
Hospital.
Statistical analysis
SPSS ver. 10.0 was used for the statistical analyses. All data
were analyzed using analysis of variance (ANOVA) fol-
lowed by a least-squares difference test. The relationships
between SMP30 levels in liver tissues and the ALT, TBiL in
plasma of animal model were analyzed by the Pearson
correlation test. P values of < 0.05 were considered signif-
icant. All data are presented as the mean ± S.E.
Results
SMP30 only elevated in plasma of ALF mice according to 
2-DE
Coinjection of GalN/LPS successfully induced the ALF
animal model (group 4) and about 10% of these mice sur-
vived (group 8). Plasma ALT and TBiL levels increased sig-
nificantly at 5 hours and 24 hours after GalN/LPS
injection (Table 1). We analyzed the plasma proteins of
the ALF mice and the other controls by 2-DE. Differen-
tially expressed protein spots were identified with soft-
ware analysis. Of these proteins, the expression of only
two protein spots was elevated in the plasma of ALF mice.
When identified by MS, these two proteins spots were the
same protein molecule, SMP30 (Figure 1A, B, C), with a
molecular weight of 33.4 kDa and an isoelectric point (pI)
of 5.16.
Validation of GalN/LPS-induced SMP30 levels in plasma by 
WB
SMP30 was selectively expressed in response to GalN/LPS
treatment, as determined by 2-DE. This result was con-
firmed by WB, as shown in Figure 1D. Plasma SMP30 lev-
els were only elevated in ALF mice treated with GalN/LPS
(group 4) compared with those of the control groups.
Moreover, plasma SMP30 levels returned to the control
level in surviving animals (group 8). This result parallels
that obtained with 2-DE.
GalN/LPS-induced expression of SMP30 protein and 
mRNA in liver tissues
To investigate whether there is a relationship between
plasma SMP30 protein levels and the expression of this
protein in liver tissues, WB analysis of liver-specific
SMP30 expression was performed. As shown in Figure 2,
SMP30 protein levels were significantly reduced in the
liver tissues of GalN/LPS-treated mice compared with the
tissues of their control counterparts (approximately 25%
and 16% on 4 and 8 group respectively, P4,8 < 0.01). There
was no significant difference in the liver SMP30 protein
levels of groups 4 and 8 (P > 0.05).
Table 1: Serum ALT and TBiL levels in mice
group saline LPS GalN GalN/LPS saline LPS GalN GalN/LPS
5 h 24 h
ALT(U/L) 45.25 ± 9.64 41.50 ± 10.11 62.13 ± 23.93 2034.00 ± 
343.68*
46.63 ± 9.75 42.13 ± 9.92 57.63 ± 12.38 1655.50 ± 
722.62*
TBiL(μmol/L) 0.34 ± 0.29 0.49 ± 0.21 0.36 ± 0.29 4.71 ± 0.65* 0.53 ± 0.33 0.50 ± 0.15 0.48 ± 0.27 3.53 ± 1.72*
*: P < 0.01 vs control groupBMC Gastroenterology 2008, 8:17 http://www.biomedcentral.com/1471-230X/8/17
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In order to investigate the relationship between expres-
sion of SMP30 in liver tissues and ALT, TBiL levels in
plasma of animal model, we calculated Pearson correla-
tion coefficients. Correlation analysis revealed significant
negative correlations between SMP30 levels and ALT, TBiL
(P < 0.01; r = -0.413 and -0.574, respectively).
RT-PCR revealed that SMP30 mRNA levels were signifi-
cantly reduced about 90% in liver tissues 24 h after GalN/
LPS treatment, but were unchanged 5 h after its adminis-
tration (Figure 3, P8 < 0.01).
Elevated plasma SMP30 levels in ALF patients
The expression of SMP30 in ALF mice caught our interest.
Therefore, we determined whether SMP30 levels are
altered in the plasma of patients with ALF. Plasma pro-
teins from patients with ALF and healthy volunteers were
analyzed by WB. As can be seen in Figure 4, SMP30 pro-
tein levels in ALF patients were significantly elevated,
about 3.65 ± 0.34 times, compared with those of the
healthy volunteers (P < 0.01).
Discussion
Our data validate previous findings and show that (1)
plasma SMP30 protein levels are significantly elevated in
Plasma SMP30 levels were only elevated in mice with ALF Figure 1
Plasma SMP30 levels were only elevated in mice with ALF. A: 2-D gel of murine plasma proteins. B: Magnified regions 
of 2-D gel of murine plasma proteins. The results shown are representative of three independent experiments. The protein 
spot corresponding to SMP30 is indicated with an arrow. C: Spectrum from LC-ESI-MS/MS analysis of the trypsin digestion 
products of senescence marker protein 30 (SMP30). D: WB analysis of plasma SMP30 levels in GalN/LPS-treated mice. Lane 
and gel 1: 5 h after saline injection; lane and gel 2: 5 h after LPS injection; lane and gel 3: 5 h after GalN injection; lane and gel 4: 
5 h after GalN/LPS injection; lane and gel 5: 24 h after saline injection; lane and gel 6: 24 h after LPS injection; lane and gel 7: 24 
h after GalN injection; lane and gel 8: 24 h after GalN/LPS injection.BMC Gastroenterology 2008, 8:17 http://www.biomedcentral.com/1471-230X/8/17
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mice and patients with ALF; (2) liver SMP30 protein levels
are significantly reduced in GalN/LPS-treated mice; and
(3) liver SMP30 mRNA levels are only reduced in those
animals that survive treatment with GalN/LPS.
In this study, we have demonstrated for the first time,
using a comparative proteomics approach, that SMP30
levels were only significantly elevated in the plasma of our
ALF animal model. Furthermore, we verified by WB that
the levels of SMP30 were increased in the plasma of ALF
mice but not in the plasma of surviving animals. This
result is consistent with the results of 2-DE. The results of
the animal experiments prompted us to determine
whether there are similar changes in humans. As we
expected, plasma SMP30 levels were significantly elevated
in ALF patients compared with those in healthy volun-
teers, according to WB analysis. These consistent results in
animals and humans suggest that plasma SMP30 is a
potential biomarker of liver injury and may even be useful
in ALF diagnosis. However, the number of patients was
small, so this result should be considered preliminary and
additional research with clinical samples should be
undertaken.
As a tissue-specific protein, SMP30 is synthesized and
expressed predominantly in the liver tissues of humans
and mice [6,7,14]. Was its abnormal increase in plasma
secondarily induced by the changes in its expression in the
liver? Conversely, WB analysis demonstrated that SMP30
protein levels were reduced in the livers of mice treated
with GalN/LPS. We speculated that the reasons for this
discrepancy in the plasma and liver levels of SMP30 in
ALF mice included (1) an increase in the membrane per-
meability of damaged hepatocytes and the necrosis of
hepatocytes, allowing the release of SMP30 into the blood
[15]; (2) a decrease in the clearance and degradation of
SMP30 from the plasma, resulting from severe hepatic
injury; and (3) some factors that stimulated other tissues
to release SMP30 into the plasma during the progress of
ALF. Importantly, we found that plasma SMP30 levels
returned to the control level in the surviving animals
(group 8), although their liver SMP30 protein levels had
decreased. This phenomenon indicates that plasma
SMP30 is probably not only a potential biomarker for the
diagnosis of ALF, but may also be useful in assessing prog-
noses in severe hepatic injury.
In this study, we found that SMP30 protein levels were
reduced in the liver tissues of GalN/LPS-treated mice. In
order to investigate the relationship between expression
of SMP30 in liver tissues and the extent of liver injury, we
calculated Pearson correlation coefficients. Correlation
analysis revealed significant negative correlations between
WB analysis of liver tissue SMP30 levels in GalN/LPS-treated  mice Figure 2
WB analysis of liver tissue SMP30 levels in GalN/LPS-
treated mice. Lane 1: 5 h after saline injection; lane 2: 5 h 
after LPS injection; lane 3: 5 h after GalN injection; lane 4: 5 h 
after GalN/LPS injection; lane 5: 24 h after saline injection; 
lane 6: 24 h after LPS injection; lane 7: 24 h after GalN injec-
tion; lane 8: 24 h after GalN/LPS injection. SMP30 levels were 
significantly reduced in the liver tissues of mice treated with 
GalN/LPS compared with those of the control groups (P < 
0.01). There was no significant difference between the 
SMP30 protein levels of groups 4 and 8 (P > 0.05).
RT-PCR analysis of liver tissue SMP30 mRNA levels in GalN/ LPS-treated mice Figure 3
RT-PCR analysis of liver tissue SMP30 mRNA levels 
in GalN/LPS-treated mice. Lane 1: 5 h after saline injec-
tion; lane 2: 5 h after LPS injection; lane 3: 5 h after GalN 
injection; lane 4: 5 h after GalN/LPS injection; lane 5: 24 h 
after saline injection; lane 6: 24 h after LPS injection; lane 7: 
24 h after GalN injection group; lane 8: 24 h after GalN/LPS 
injection. SMP30 mRNA levels were significantly reduced in 
liver tissues only at 24 h after GalN/LPS administration (P8 < 
0.01 vs other control groups).BMC Gastroenterology 2008, 8:17 http://www.biomedcentral.com/1471-230X/8/17
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SMP30 levels in liver tissues and ALT, TBiL levels in
plasma (P < 0.01). These negative correlations indicate
that when severe liver injury develops, the downregula-
tion of SMP30 in liver tissues would allow tissue regener-
ation. Other researchers have also found that liver SMP30
protein levels decreased when animals were administered
carbon tetrachloride [16,17], phenobarbital [18], or LPS
[19]. Liver tissue is the most important target organ of
chemical injury. Hepatocytes can be induced to proliferate
to ensure normal liver function. Many previous studies
have found that the overexpression of SMP30 suppresses
the proliferation of liver cells [17,20]. In the process of
hepatocyte necrosis, this decrease in SMP30 is perhaps a
self-protective mechanism that reduces its effect of inhib-
iting proliferation. SMP30 mRNA levels were especially
significantly reduced in the mice that survived treatment
with GalN/LPS. This result suggests that the decreased
expression of liver SMP30 is controlled at the level of tran-
scription. More importantly, the liver tissues of the mice
that survived treatment with GalN/LPS displayed hepato-
cyte proliferation. Therefore, there may be factors that reg-
ulate the expression of SMP30 mRNA, and the consequent
low levels of SMP30 protein participate in the regulation
of hepatocyte proliferation. Thus, a minority of mice
recover spontaneously.
Conclusion
This study achieved its primary purpose of validating the
expression of one candidate biomarker discovered using
2-DE and LC-ESI-MS/MS. Comparative proteomic analy-
sis and continuing validation research led to the identifi-
cation of a novel protein, SMP30, which is not only a
potential biomarker of ALF diagnosis even prognosis, but
may also play a very important role in the self-protective
mechanism that facilitates survival in ALF.
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